spacer
spacer

PDBsum entry 1idb

Go to PDB code: 
protein ligands Protein-protein interface(s) links
Hydrolase/hydrolase inhibitor PDB id
1idb

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
99 a.a. *
Ligands
0DO
Waters ×42
* Residue conservation analysis
PDB id:
1idb
Name: Hydrolase/hydrolase inhibitor
Title: Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere
Structure: Protease. Chain: a, b. Engineered: yes
Source: Human immunodeficiency virus 2. Organism_taxid: 11709. Gene: pol. Expressed in: escherichia coli. Expression_system_taxid: 562
Biol. unit: Trimer (from PQS)
Resolution:
2.20Å     R-factor:   0.180    
Authors: L.Tong,P.C.Anderson
Key ref:
L.Tong et al. (1995). Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere. Structure, 3, 33-40. PubMed id: 7743130 DOI: 10.1016/S0969-2126(01)00133-2
Date:
19-Oct-94     Release date:   26-Jan-95    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chains
P04584  (POL_HV2RO) -  Gag-Pol polyprotein from Human immunodeficiency virus type 2 subtype A (isolate ROD)
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
1464 a.a.
99 a.a.
Key:    Secondary structure  CATH domain

 Enzyme reactions 
   Enzyme class 1: E.C.2.7.7.-  - ?????
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 2: E.C.2.7.7.49  - RNA-directed Dna polymerase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
DNA(n)
+ 2'-deoxyribonucleoside 5'-triphosphate
= DNA(n+1)
+ diphosphate
   Enzyme class 3: E.C.2.7.7.7  - DNA-directed Dna polymerase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
DNA(n)
+ 2'-deoxyribonucleoside 5'-triphosphate
= DNA(n+1)
+ diphosphate
   Enzyme class 4: E.C.3.1.-.-
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 5: E.C.3.1.13.2  - exoribonuclease H.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: Exonucleolytic cleavage to 5'-phosphomonoester oligonucleotides in both 5'- to 3'- and 3'- to 5'-directions.
   Enzyme class 6: E.C.3.1.26.13  - retroviral ribonuclease H.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 7: E.C.3.4.23.47  - HIV-2 retropepsin.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
Note, where more than one E.C. class is given (as above), each may correspond to a different protein domain or, in the case of polyprotein precursors, to a different mature protein.
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    reference    
 
 
DOI no: 10.1016/S0969-2126(01)00133-2 Structure 3:33-40 (1995)
PubMed id: 7743130  
 
 
Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere.
L.Tong, S.Pav, S.Mui, D.Lamarre, C.Yoakim, P.Beaulieu, P.C.Anderson.
 
  ABSTRACT  
 
BACKGROUND: The HIV protease is essential for the life cycle of the virus and is an important target for the development of therapeutic treatments against AIDS. The structures of HIV protease in complex with different inhibitors have helped in understanding the interactions between inhibitors and the protease and in the design and optimization of HIV protease inhibitors. RESULTS: We report here crystal structures at up to 1.7 A resolution of the homodimeric HIV-2 protease in complex with seven inhibitors containing the hydroxyethylamine dipeptide isostere. A novel dimethylphenoxyacetyl group that is present in some of these inhibitors is inserted between residues 48' and 49' in the flap of the protease and residues 29' and 30' (where a prime indicates a residue in the second monomer), which undergo a conformational change to accommodate the phenyl ring of the inhibitor. CONCLUSIONS: This study shows that besides the residues in the flap and residues 79-81 in the S1 substrate-binding pocket which undergo conformational changes upon inhibitor binding, residues 29 and 30 can also adapt their conformation to fit certain inhibitors. Conformational flexibility of the HIV protease plays an important role in inhibitor binding.
 
  Selected figure(s)  
 
Figure 5.
Figure 5. The binding modes of the inhibitors. (a) Overlap of the bound conformation of the long inhibitors 1 (red), 2 (cyan) and 3 (black). (b) Overlap of the bound conformation of the short inhibitors 4 (black), 5 (cyan), 6 (pink) and 7 (green). (c ) Overlap of the bound conformation of the long inhibitor 1 (red) and the short inhibitor 7 (green) . Figure 5. The binding modes of the inhibitors. (a) Overlap of the bound conformation of the long inhibitors 1 (red), 2 (cyan) and 3 (black). (b) Overlap of the bound conformation of the short inhibitors 4 (black), 5 (cyan), 6 (pink) and 7 (green). (c ) Overlap of the bound conformation of the long inhibitor 1 (red) and the short inhibitor 7 (green) .
Figure 6.
Figure 6. (a) Hydrogen-bonding interactions between inhibitor 1 and the protease. (b) The interactions between the hydroxyl of the isostere and the catalytic aspartic acid residues . Figure 6. (a) Hydrogen-bonding interactions between inhibitor 1 and the protease. (b) The interactions between the hydroxyl of the isostere and the catalytic aspartic acid residues .
 
  The above figures are reprinted by permission from Cell Press: Structure (1995, 3, 33-40) copyright 1995.  
  Figures were selected by an automated process.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
19798742 J.M.Louis, R.Ishima, A.Aniana, and J.M.Sayer (2009).
Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 protease.
  Protein Sci, 18, 2442-2453.  
18834890 A.Y.Kovalevsky, J.M.Louis, A.Aniana, A.K.Ghosh, and I.T.Weber (2008).
Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease.
  J Mol Biol, 384, 178-192.
PDB codes: 3ebz 3ec0 3ecg
17523154 Y.Zhao, and M.F.Sanner (2007).
FLIPDock: docking flexible ligands into flexible receptors.
  Proteins, 68, 726-737.  
16941468 H.B.Thorsteinsdottir, T.Schwede, V.Zoete, and M.Meuwly (2006).
How inaccuracies in protein structure models affect estimates of protein-ligand interactions: computational analysis of HIV-I protease inhibitor binding.
  Proteins, 65, 407-423.  
15767422 P.Bagossi, T.Sperka, A.Fehér, J.Kádas, G.Zahuczky, G.Miklóssy, P.Boross, and J.Tözsér (2005).
Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites.
  J Virol, 79, 4213-4218.  
15540219 H.M.Abdel-Rahman, N.A.el-Koussi, G.S.Alkaramany, A.F.Youssef, and Y.Kiso (2004).
A novel dipeptide-based HIV protease inhibitor containing allophenylnorstatine.
  Arch Pharm (Weinheim), 337, 587-598.  
12838268 S.J.Teague (2003).
Implications of protein flexibility for drug discovery.
  Nat Rev Drug Discov, 2, 527-541.  
11276081 D.J.Diller, and K.M.Merz (2001).
High throughput docking for library design and library prioritization.
  Proteins, 43, 113-124.  
10651268 C.M.Stultz, and M.Karplus (1999).
MCSS functionality maps for a flexible protein.
  Proteins, 37, 512-529.  
9646869 A.Wlodawer, and J.Vondrasek (1998).
Inhibitors of HIV-1 protease: a major success of structure-assisted drug design.
  Annu Rev Biophys Biomol Struct, 27, 249-284.  
  9835517 H.L.Sham, D.J.Kempf, A.Molla, K.C.Marsh, G.N.Kumar, C.M.Chen, W.Kati, K.Stewart, R.Lal, A.Hsu, D.Betebenner, M.Korneyeva, S.Vasavanonda, E.McDonald, A.Saldivar, N.Wideburg, X.Chen, P.Niu, C.Park, V.Jayanti, B.Grabowski, G.R.Granneman, E.Sun, A.J.Japour, J.M.Leonard, J.J.Plattner, and D.W.Norbeck (1998).
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.
  Antimicrob Agents Chemother, 42, 3218-3224.  
  9145853 D.Lamarre, G.Croteau, E.Wardrop, L.Bourgon, D.Thibeault, C.Clouette, M.Vaillancourt, E.Cohen, C.Pargellis, C.Yoakim, and P.C.Anderson (1997).
Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease.
  Antimicrob Agents Chemother, 41, 965-971.  
  8995629 G.Croteau, L.Doyon, D.Thibeault, G.McKercher, L.Pilote, and D.Lamarre (1997).
Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors.
  J Virol, 71, 1089-1096.  
9346283 G.Lange-Savage, H.Berchtold, A.Liesum, K.H.Budt, A.Peyman, J.Knolle, J.Sedlacek, M.Fabry, and R.Hilgenfeld (1997).
Structure of HOE/BAY 793 complexed to human immunodeficiency virus (HIV-1) protease in two different crystal forms--structure/function relationship and influence of crystal packing.
  Eur J Biochem, 248, 313-322.
PDB codes: 1vij 1vik
  8648711 L.Doyon, G.Croteau, D.Thibeault, F.Poulin, L.Pilote, and D.Lamarre (1996).
Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.
  J Virol, 70, 3763-3769.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB codes are shown on the right.

 

spacer

spacer